Longitudinal Assessment of Tumor-Infiltrating Lymphocytes in Primary Breast Cancer Following Neoadjuvant Radiation Therapy

Tumor-infiltrating lymphocytes (TILs) have prognostic significance in several cancers, including breast cancer. Despite interest in combining radiation therapy with immunotherapy, little is known about the effect of radiation therapy itself on the tumor-immune microenvironment, including TILs. Here,...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:International journal of radiation oncology, biology, physics Ročník 120; číslo 3; s. 862
Hlavní autoři: Yoneyama, Miki, Zormpas-Petridis, Konstantinos, Robinson, Ruth, Sobhani, Faranak, Provenzano, Elena, Steel, Harriet, Lightowlers, Sara, Towns, Catherine, Castillo, Simon P, Anbalagan, Selvakumar, Lund, Tom, Wennerberg, Erik, Melcher, Alan, Coles, Charlotte E, Roxanis, Ioannis, Yuan, Yinyin, Somaiah, Navita
Médium: Journal Article
Jazyk:angličtina
Vydáno: 01.11.2024
ISSN:1879-355X, 1879-355X
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Tumor-infiltrating lymphocytes (TILs) have prognostic significance in several cancers, including breast cancer. Despite interest in combining radiation therapy with immunotherapy, little is known about the effect of radiation therapy itself on the tumor-immune microenvironment, including TILs. Here, we interrogated longitudinal dynamics of TILs and systemic lymphocytes in patient samples taken before, during, and after neoadjuvant radiation therapy (NART) from PRADA and Neo-RT breast clinical trials.PURPOSETumor-infiltrating lymphocytes (TILs) have prognostic significance in several cancers, including breast cancer. Despite interest in combining radiation therapy with immunotherapy, little is known about the effect of radiation therapy itself on the tumor-immune microenvironment, including TILs. Here, we interrogated longitudinal dynamics of TILs and systemic lymphocytes in patient samples taken before, during, and after neoadjuvant radiation therapy (NART) from PRADA and Neo-RT breast clinical trials.We manually scored stromal TILs (sTILs) from longitudinal tumor samples using standardized guidelines as well as deep learning-based scores at cell-level (cTIL) and cell- and tissue-level combination analyses (SuperTIL). In parallel, we interrogated absolute lymphocyte counts from routine blood tests at corresponding time points during treatment. Exploratory analyses studied the relationship between TILs and pathologic complete response (pCR) and long-term outcomes.METHODS AND MATERIALSWe manually scored stromal TILs (sTILs) from longitudinal tumor samples using standardized guidelines as well as deep learning-based scores at cell-level (cTIL) and cell- and tissue-level combination analyses (SuperTIL). In parallel, we interrogated absolute lymphocyte counts from routine blood tests at corresponding time points during treatment. Exploratory analyses studied the relationship between TILs and pathologic complete response (pCR) and long-term outcomes.Patients receiving NART experienced a significant and uniform decrease in sTILs that did not recover at the time of surgery (P < .0001). This lymphodepletive effect was also mirrored in peripheral blood. Our SuperTIL deep learning score showed good concordance with manual sTILs and importantly performed comparably to manual scores in predicting pCR from diagnostic biopsies. The analysis suggested an association between baseline sTILs and pCR, as well as sTILs at surgery and relapse, in patients receiving NART.RESULTSPatients receiving NART experienced a significant and uniform decrease in sTILs that did not recover at the time of surgery (P < .0001). This lymphodepletive effect was also mirrored in peripheral blood. Our SuperTIL deep learning score showed good concordance with manual sTILs and importantly performed comparably to manual scores in predicting pCR from diagnostic biopsies. The analysis suggested an association between baseline sTILs and pCR, as well as sTILs at surgery and relapse, in patients receiving NART.This study provides novel insights into TIL dynamics in the context of NART in breast cancer and demonstrates the potential for artificial intelligence to assist routine pathology. We have identified trends that warrant further interrogation and have a bearing on future radioimmunotherapy trials.CONCLUSIONSThis study provides novel insights into TIL dynamics in the context of NART in breast cancer and demonstrates the potential for artificial intelligence to assist routine pathology. We have identified trends that warrant further interrogation and have a bearing on future radioimmunotherapy trials.
AbstractList Tumor-infiltrating lymphocytes (TILs) have prognostic significance in several cancers, including breast cancer. Despite interest in combining radiation therapy with immunotherapy, little is known about the effect of radiation therapy itself on the tumor-immune microenvironment, including TILs. Here, we interrogated longitudinal dynamics of TILs and systemic lymphocytes in patient samples taken before, during, and after neoadjuvant radiation therapy (NART) from PRADA and Neo-RT breast clinical trials.PURPOSETumor-infiltrating lymphocytes (TILs) have prognostic significance in several cancers, including breast cancer. Despite interest in combining radiation therapy with immunotherapy, little is known about the effect of radiation therapy itself on the tumor-immune microenvironment, including TILs. Here, we interrogated longitudinal dynamics of TILs and systemic lymphocytes in patient samples taken before, during, and after neoadjuvant radiation therapy (NART) from PRADA and Neo-RT breast clinical trials.We manually scored stromal TILs (sTILs) from longitudinal tumor samples using standardized guidelines as well as deep learning-based scores at cell-level (cTIL) and cell- and tissue-level combination analyses (SuperTIL). In parallel, we interrogated absolute lymphocyte counts from routine blood tests at corresponding time points during treatment. Exploratory analyses studied the relationship between TILs and pathologic complete response (pCR) and long-term outcomes.METHODS AND MATERIALSWe manually scored stromal TILs (sTILs) from longitudinal tumor samples using standardized guidelines as well as deep learning-based scores at cell-level (cTIL) and cell- and tissue-level combination analyses (SuperTIL). In parallel, we interrogated absolute lymphocyte counts from routine blood tests at corresponding time points during treatment. Exploratory analyses studied the relationship between TILs and pathologic complete response (pCR) and long-term outcomes.Patients receiving NART experienced a significant and uniform decrease in sTILs that did not recover at the time of surgery (P < .0001). This lymphodepletive effect was also mirrored in peripheral blood. Our SuperTIL deep learning score showed good concordance with manual sTILs and importantly performed comparably to manual scores in predicting pCR from diagnostic biopsies. The analysis suggested an association between baseline sTILs and pCR, as well as sTILs at surgery and relapse, in patients receiving NART.RESULTSPatients receiving NART experienced a significant and uniform decrease in sTILs that did not recover at the time of surgery (P < .0001). This lymphodepletive effect was also mirrored in peripheral blood. Our SuperTIL deep learning score showed good concordance with manual sTILs and importantly performed comparably to manual scores in predicting pCR from diagnostic biopsies. The analysis suggested an association between baseline sTILs and pCR, as well as sTILs at surgery and relapse, in patients receiving NART.This study provides novel insights into TIL dynamics in the context of NART in breast cancer and demonstrates the potential for artificial intelligence to assist routine pathology. We have identified trends that warrant further interrogation and have a bearing on future radioimmunotherapy trials.CONCLUSIONSThis study provides novel insights into TIL dynamics in the context of NART in breast cancer and demonstrates the potential for artificial intelligence to assist routine pathology. We have identified trends that warrant further interrogation and have a bearing on future radioimmunotherapy trials.
Author Roxanis, Ioannis
Yuan, Yinyin
Lightowlers, Sara
Anbalagan, Selvakumar
Yoneyama, Miki
Melcher, Alan
Provenzano, Elena
Zormpas-Petridis, Konstantinos
Towns, Catherine
Castillo, Simon P
Robinson, Ruth
Lund, Tom
Sobhani, Faranak
Coles, Charlotte E
Wennerberg, Erik
Steel, Harriet
Somaiah, Navita
Author_xml – sequence: 1
  givenname: Miki
  surname: Yoneyama
  fullname: Yoneyama, Miki
– sequence: 2
  givenname: Konstantinos
  surname: Zormpas-Petridis
  fullname: Zormpas-Petridis, Konstantinos
– sequence: 3
  givenname: Ruth
  surname: Robinson
  fullname: Robinson, Ruth
– sequence: 4
  givenname: Faranak
  surname: Sobhani
  fullname: Sobhani, Faranak
– sequence: 5
  givenname: Elena
  surname: Provenzano
  fullname: Provenzano, Elena
– sequence: 6
  givenname: Harriet
  surname: Steel
  fullname: Steel, Harriet
– sequence: 7
  givenname: Sara
  surname: Lightowlers
  fullname: Lightowlers, Sara
– sequence: 8
  givenname: Catherine
  surname: Towns
  fullname: Towns, Catherine
– sequence: 9
  givenname: Simon P
  surname: Castillo
  fullname: Castillo, Simon P
– sequence: 10
  givenname: Selvakumar
  surname: Anbalagan
  fullname: Anbalagan, Selvakumar
– sequence: 11
  givenname: Tom
  surname: Lund
  fullname: Lund, Tom
– sequence: 12
  givenname: Erik
  surname: Wennerberg
  fullname: Wennerberg, Erik
– sequence: 13
  givenname: Alan
  surname: Melcher
  fullname: Melcher, Alan
– sequence: 14
  givenname: Charlotte E
  surname: Coles
  fullname: Coles, Charlotte E
– sequence: 15
  givenname: Ioannis
  surname: Roxanis
  fullname: Roxanis, Ioannis
– sequence: 16
  givenname: Yinyin
  surname: Yuan
  fullname: Yuan, Yinyin
– sequence: 17
  givenname: Navita
  surname: Somaiah
  fullname: Somaiah, Navita
BookMark eNpNj8FLwzAchYNMcE7_Aw85emlN0jZpj3M4HRQVmeBtZOmvW0qb1CRV6l9vRQ_CB-8dHh-8czQz1gBCV5TElFB-08S6cXbfx4ywNCYTPDtBc5qLIkqy7G32r5-hc-8bQgilIp2jr9Kagw5DpY1s8dJ78L4DE7Ct8XborIs2ptZtcDJoc8Dl2PVHq8YAHmuDn53upBvxrQPpA15Jo8DhtW1b-_kzfwQrq2b4kJPwRVZ6kliDt0dwsh8v0GktWw-Xf7lAr-u77eohKp_uN6tlGamEiBApBblSlRSk4jxhivIim_6JKklJzlSiiKhzmtYcMgkM8n0umWCFyvJaSM4ZW6DrX2_v7PsAPuw67RW0rTRgB79LSCqKCS7YN6b_Z7g
CitedBy_id crossref_primary_10_1097_PPO_0000000000000773
crossref_primary_10_1038_s41467_025_62249_0
crossref_primary_10_1038_s41523_025_00796_x
crossref_primary_10_3390_cancers16162895
ContentType Journal Article
Copyright Copyright © 2024 Elsevier Inc. All rights reserved.
Copyright_xml – notice: Copyright © 2024 Elsevier Inc. All rights reserved.
DBID 7X8
DOI 10.1016/j.ijrobp.2024.04.065
DatabaseName MEDLINE - Academic
DatabaseTitle MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
Database_xml – sequence: 1
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1879-355X
GroupedDBID ---
--K
.1-
.FO
0R~
1B1
1P~
1RT
1~5
4.4
457
4G.
53G
5RE
7-5
7X8
AAEDT
AAEDW
AALRI
AAWTL
AAXUO
ABJNI
ABLJU
ABNEU
ABOCM
ABUDA
ACGFS
ACIUM
ADBBV
AENEX
AEVXI
AFJKZ
AFRHN
AFTJW
AHHHB
AITUG
AJUYK
AKRWK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
BELOY
DU5
EBS
EFKBS
F5P
FDB
GBLVA
HED
HMO
IHE
J1W
KOM
LX3
M41
MO0
O9-
OC~
OO-
RNS
ROL
RPZ
SDG
SEL
SES
SEW
SSZ
UV1
XH2
Z5R
~S-
ID FETCH-LOGICAL-c307t-cce8ccda70d6632c16950657d34082c3c07f814f6e5ae2e8b8a2729c58f7a6622
IEDL.DBID 7X8
ISSN 1879-355X
IngestDate Thu Sep 25 08:53:23 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c307t-cce8ccda70d6632c16950657d34082c3c07f814f6e5ae2e8b8a2729c58f7a6622
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PQID 3047947967
PQPubID 23479
ParticipantIDs proquest_miscellaneous_3047947967
PublicationCentury 2000
PublicationDate 20241101
PublicationDateYYYYMMDD 2024-11-01
PublicationDate_xml – month: 11
  year: 2024
  text: 20241101
  day: 01
PublicationDecade 2020
PublicationTitle International journal of radiation oncology, biology, physics
PublicationYear 2024
SSID ssj0001174
Score 2.4685671
Snippet Tumor-infiltrating lymphocytes (TILs) have prognostic significance in several cancers, including breast cancer. Despite interest in combining radiation therapy...
SourceID proquest
SourceType Aggregation Database
StartPage 862
Title Longitudinal Assessment of Tumor-Infiltrating Lymphocytes in Primary Breast Cancer Following Neoadjuvant Radiation Therapy
URI https://www.proquest.com/docview/3047947967
Volume 120
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3PS8MwFA7qRLz4W_xNBK_BNmmT9CQ6HApzDJnQ22iTVDq00a5V5l9vknbu4EXw_g4l78vL17yX7wPgggUCE-l5hrmZNAS-p1BKeIhCSSWPmMew5M5sgg0GPI6jYXvhNm3HKuc10RVqqYW9I78kTgudRZRdvb0j6xplu6uthcYy6BBDZSyqWbxQC_cbFWZrqI3MuRrPn865-a58UurUKlbiwImd0vBXOXZnTG_zv1-3BTZadgmvGzhsgyVV7IC1h7Z_vgu--tr6E9Uyd2E_qpxQZ3BUv-oS3RdZ_uKkdItn2J-ZXGsxM3QU5gUcNsoU8MYOslewawFTwp5Bkv604QOlEzmpDTev4KPVPLBJh6NGt2APPPVuR9071LovIGH2fYWEUFwImTBPGlaChU-j0CwSk8R6VAsiPJZxP8ioChOFFU95gg1TFyHPWEIpxvtgpdCFOgDQcBCZpL4MsUcCRUQqM49gSVVqfhZ9Qg_B-XxVxwbdtmWRFErX0_FiXY_-EHMM1m06m6eCJ6CTmR2sTsGq-KjyaXnmwPENHpPFqg
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Longitudinal+Assessment+of+Tumor-Infiltrating+Lymphocytes+in+Primary+Breast+Cancer+Following+Neoadjuvant+Radiation+Therapy&rft.jtitle=International+journal+of+radiation+oncology%2C+biology%2C+physics&rft.au=Yoneyama%2C+Miki&rft.au=Zormpas-Petridis%2C+Konstantinos&rft.au=Robinson%2C+Ruth&rft.au=Sobhani%2C+Faranak&rft.date=2024-11-01&rft.issn=1879-355X&rft.eissn=1879-355X&rft.volume=120&rft.issue=3&rft.spage=862&rft_id=info:doi/10.1016%2Fj.ijrobp.2024.04.065&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1879-355X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1879-355X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1879-355X&client=summon